Akten

Generic Name: lidocaine hydrochloride ophthalmic gel
Date of Approval: October 7, 2008
Company: Akorn, Inc.
Treatment for: Ocular Anesthesia

FDA Approves Akten

The United States Food and Drug Administration (FDA) has approved Akten (lidocaine hydrochloride) Ophthalmic Gel 3.5%, a topical, ocular anesthetic formulation.

Akten is a novel, unit dose, preservative free lidocaine gel product, stored at room temperature and intended to be used in any ocular procedure that requires a topical anesthetic agent including cataract surgery, refractive surgery, Lasik surgery, and intravitreal injection.

Slideshow: Worried About Ebola? You’re More Likely to Get These 10 Serious Infections

Highlights of Akten Prescribing Information

Indications and Usage

Akten is a local anesthetic indicated for ocular surface anesthesia during ophthalmologic procedures.

Dosage and Administration

The recommended dose of Akten is 2 drops applied to the ocular surface in the area of the planned procedure. Additional anesthesia may be reapplied as needed.

Dosage Forms and Strengths

Akten 3.5% (35 mg/mL) Ophthalmic Gel

Warnings and Precautions

  • Not for Injection
  • Corneal Opacification- prolonged use of a topical ocular anesthetic may produce permanent corneal opacification and ulceration with accompanying visual loss

Adverse Reactions

Most common adverse reactions are conjunctival hyperemia, corneal epithelial changes, headache, and burning upon instillation.

To report SUSPECTED ADVERSE REACTIONS, contact Akorn at 1-800-932-5676 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For more information, please visit www.akorn.com.

Hide
(web3)